Evidence landscapes, kept current.

Published landscapes (17)

• GLP-1 receptor in Obesity
  6 primary identifiers · 6 sponsors · 2 evidence types
• Lp(a) in Atherosclerotic cardiovascular disease
  9 primary identifiers · 6 sponsors · 2 evidence types
• Amylin receptor in Obesity
  8 primary identifiers · 5 sponsors · 2 evidence types
• TROP2 in Breast cancer
  8 primary identifiers · 8 sponsors · 2 evidence types
• Cellular senescence in Age-related functional decline
  13 primary identifiers · 12 sponsors · 2 evidence types
• PD-1/VEGF bispecific in Non-small cell lung cancer
  8 primary identifiers · 7 sponsors · 2 evidence types
• FGF21 pathway in Metabolic dysfunction-associated steatohepatitis
  16 primary identifiers · 8 sponsors · 2 evidence types
• Thyroid hormone receptor beta in Metabolic dysfunction-associated steatohepatitis
  13 primary identifiers · 9 sponsors · 2 evidence types
• WRN helicase in MSI-H colorectal cancer
  6 primary identifiers · 6 sponsors · 2 evidence types
• TL1A in Ulcerative colitis
  6 primary identifiers · 4 sponsors · 2 evidence types
• Amyloid-beta in Alzheimer's disease
  7 primary identifiers · 4 sponsors · 2 evidence types
• Myostatin/activin (ActRII) in Obesity (lean-mass preservation)
  5 primary identifiers · 5 sponsors · 2 evidence types
• HER2 in Breast cancer
  10 primary identifiers · 8 sponsors · 2 evidence types
• CDK4/6 in HR-positive breast cancer
  8 primary identifiers · 7 sponsors · 2 evidence types
• Tau in Alzheimer's disease
  5 primary identifiers · 5 sponsors · 2 evidence types
• KRAS G12C in Non-small cell lung cancer
  7 primary identifiers · 7 sponsors · 2 evidence types
• PARP1/2 in Ovarian cancer
  8 primary identifiers · 7 sponsors · 2 evidence types

Emerging — tracked, not yet published (1)

These areas do not yet meet our publication floor. We hold them rather than drop them, and promote them the moment the evidence matures — a landscape should not be invisible just because it is early.

• ALK7 / activin pathway in Obesity — 3 identifiers; unique-identifiers 3 < 5; evidence-types 1 < 2

How these are built

• Pairs are derived from the evidence itself — a target and an indication appear together only because a primary record links them as a therapeutic hypothesis. There is no keyword list and no generated topic list anywhere in the pipeline.
• A landscape publishes only when it clears every floor: enough distinct primary identifiers, more than one sponsor, and more than one class of evidence. Where the record is thin, we say so rather than filling the gap with prose.
• We report what the record states. No efficacy claims; computational findings are pending wet-lab confirmation.